Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05890014
Other study ID # UReading mothers study
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 14, 2023
Est. completion date March 2024

Study information

Verified date May 2023
Source University of Reading
Contact Daniel Lamport, PhD
Phone 0118 378 5032
Email daniel.lamport@reading.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The baby blues are a significant event which can occur immediately following childbirth and is a normal experience occurring in up to 76% of new mothers, characterised by mood swings, irritability, crying spells and sadness typically lasting 10-14 days. Research suggests that the more severe and longer duration of the baby blues, the higher risk of later postnatal mood disorders. Therefore, this represents a critical period which could benefit from an intervention which may prevent symptom onset or an increase in the severity of mood disorders later in the postpartum. Flavonoids are a plant bioactive found in certain fruits vegetables and beverages. Evidence suggests that consumption of flavonoid rich foods can improve physical health, mood and cognition. Prior research investigating flavonoid intervention in mothers in the first 6 months and 1 year postpartum found significant benefits to mood in the new mothers after daily flavonoid supplementation, showing promise for the management of mood in a key period for mothers, where risk of PND is high. The immediate postpartum also represents a period of cognitive changes reported to affect up to 80% of new mothers. In addition, women during this time are at an increased risk of high blood pressure and hypertension, which is thought to be a risk factor for the onset and severity of depressive symptoms and cognitive decrements. Flavonoids have been reported to improve cognition and cardiovascular health, therefore, introducing a flavonoid intervention during the immediate postpartum could have benefits to cognition and blood pressure in new mothers. The aim of the current study will be to explore whether the implementation of a high flavonoid diet across a 30-day period will positively affect maternal mental health, cognition and blood pressure. Participants will be assigned to one of three groups; high flavonoid diet, low flavonoid diet or a control condition for 30-days, starting at days 0-4 after birth. They will have visits from the researcher at 6 separate time points between the third trimester and 12 weeks postpartum. At each visit, participants will be asked to complete mood questionnaires (PANAS-NOW, EPDS, PSAS, STAI, EPDS-P) followed by a cognitive battery (MANT, Spatial n-back, RAVLT and PRMQ) and blood pressure recordings (systolic and diastolic blood pressure). Between visits, participants will be contacted by the researcher to record retrospective 24hr food recalls (Intake24).


Description:

The study will employ a between-groups, randomised, controlled, participant-blind design with three groups and six time points. Participants will be allocated to one of three groups; a high flavonoid condition (consumption of 2 portions of flavonoid rich food per day), low flavonoid condition (consumption of one portion of flavonoid rich food per day) and a control (no change to diet). Participants will be quasi-randomised to condition based on their baseline flavonoid intake, taken at Timepoint 1 using the EPIC-Norfolk Food Frequency Questionnaire to ensure there is an even spread of baseline flavonoid consumption in participants across all conditions. At this timepoint, participants will additionally complete the Immediate Mood Scaler. Participants will be recruited at any stage of their pregnancy though testing will not take place until their third trimester (weeks 27+). Participants will be invited to a study investigating diet mood and cognition. The study will take place in person, at participant homes over 6 time points; 1) a screening session, 2) time 1 (third trimester), 3) time 2 (after birth 0-4 days, pre intervention), 4) time 3 (mid-way through intervention ~15 days), 5) time 4 (post-intervention ~30 days) and 6) time 5 (follow up, 12 weeks postpartum). Interested participants will be invited to an in-person screening session. Once participants have consented to taking part, they will be asked to provide some demographic information (e.g. age, occupation, health or psychological diagnosis). Participants will then complete practice versions of the cognitive tests. At each timepoint, the experimenter will visit participants to complete outcome measures (PANAS-NOW, EPDS, PSAS, STAI, EPDS-P, MANT, Spatial n-back, RAVLT and PRMQ, Systolic and Diastolic blood pressure). Over the course of the study, participants will be contacted at nine random timepoints to complete retrospective 24hr food recalls using the software Intake24. Participants in the flavonoid intervention groups will be contacted by the researcher shortly before time 2 where they will be sent a list of the intervention foods and asked to choose a food item which the researcher will bring to the testing session. This is to ensure that participants can start the intervention after the testing session at time 2 without needing to visit a supermarket during this sensitive time. During this session, participants will also be asked some questions about the baby and birth experience (e.g. how old their infant is, infants sex, mode of delivery, birth complications). After the outcome measures have been taken, participants will be informed of their condition and instructed to begin the intervention. The two intervention groups will also be asked to keep a food log of their selected intervention foods for the 30-day period. At the final timepoint, upon completion of outcome measures, participants will receive the debrief document and they will receive information about payment and dietary assessment via email. Participants will also be reminded of their right to withdraw their data from the study if they wish. Helplines and support web links will be provided to all participants as well as encouragement for participants to contact their GP should they wish to seek support. Helplines and weblinks include Samaritans UK and PANDAS Foundation. Weblinks to NHS, MIND and the Association for Postnatal Illness.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 2024
Est. primary completion date March 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must be pregnant (reliant on mothers' self-reporting) Exclusion Criteria: - Participants beyond 38 weeks of their pregnancy (reliant on mothers' self reporting)

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Flavonoid-rich diet
Inclusion of foods rich in flavonoids.

Locations

Country Name City State
United Kingdom University of Reading Reading Berkshire

Sponsors (1)

Lead Sponsor Collaborator
University of Reading

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other General diet Participants will complete a food frequency questionnaire at baseline using the EPIC FFQ. This measures contains a list of foods/drinks and the participant needs to state how often they consume each food/drink to assess participants' general diet. Baseline only
Other 24-hr dietary recall Measured using Intake24. This tool will contact participants asking to provide details of all the foods consumed in the previous 24-hours.The participants can do this from their phone via weblink whereby participants self-report the food they consumed, time eaten, food portion sizes and preparation in addition to any dietary supplements. This timeframe will include three measures of 24hr recall (2 weekday and 1 weekend recording). Pregnancy (up to 10 weeks before birth date)
Other 24-hr dietary recall Measured using Intake24. This tool will contact participants asking to provide details of all the foods consumed in the previous 24-hours.The participants can do this from their phone via weblink whereby participants self-report the food they consumed, time eaten, food portion sizes and preparation in addition to any dietary supplements. This timeframe will include three measures of 24hr recall (2 weekday and 1 weekend recording). Postpartum during intervention (up to 34 days after birth)
Other 24-hr dietary recall Measured using Intake24. This tool will contact participants asking to provide details of all the foods consumed in the previous 24-hours.The participants can do this from their phone via weblink whereby participants self-report the food they consumed, time eaten, food portion sizes and preparation in addition to any dietary supplements. This timeframe will include three measures of 24hr recall (2 weekday and 1 weekend recording). Postpartum after intervention (up to 12 weeks after birth)
Primary Mean depressive symptoms Assessed using scores from the Edinburgh Postnatal Depression Scale measure. Higher scores indicate higher levels of depressive symptoms. This questionnaire contains 10 items where participants rate how they have been feeling over the past 7 days on a 4-point Likert scale. The EPDS was designed for women who are pregnant or have just had a baby and has shown to be an efficient and effective way of identifying patients at risk for perinatal depression. This measure is suitable for use in new mothers and fathers. Days 0-4 postpartum
Primary Mean depressive symptoms Assessed using scores from the Edinburgh Postnatal Depression Scale measure. Higher scores indicate higher levels of depressive symptoms. This questionnaire contains 10 items where participants rate how they have been feeling over the past 7 days on a 4-point Likert scale. The EPDS was designed for women who are pregnant or have just had a baby and has shown to be an efficient and effective way of identifying patients at risk for perinatal depression. This measure is suitable for use in new mothers and fathers. 2 weeks postpartum
Primary Mean depressive symptoms Assessed using scores from the Edinburgh Postnatal Depression Scale measure. Higher scores indicate higher levels of depressive symptoms. This questionnaire contains 10 items where participants rate how they have been feeling over the past 7 days on a 4-point Likert scale. The EPDS was designed for women who are pregnant or have just had a baby and has shown to be an efficient and effective way of identifying patients at risk for perinatal depression. This measure is suitable for use in new mothers and fathers. 4 weeks postpartum
Primary Mean depressive symptoms Assessed using scores from the Edinburgh Postnatal Depression Scale measure. Higher scores indicate higher levels of depressive symptoms. This questionnaire contains 10 items where participants rate how they have been feeling over the past 7 days on a 4-point Likert scale. The EPDS was designed for women who are pregnant or have just had a baby and has shown to be an efficient and effective way of identifying patients at risk for perinatal depression. This measure is suitable for use in new mothers and fathers. 12 weeks postpartum
Primary Mean state anxiety Assessed using scores from the State-Trait Anxiety Inventory- State scale. Higher scores indicate higher levels of anxiety. This questionnaire is a measure of state and trait anxiety containing 40 items in total (20 for trait; 20 for state). Only the state scale (20 items) will be used in current research to measure situational anxiety. Participants are asked to agree or disagree with anxiety-related statements on a scale of 1-4. Days 0-4 postpartum
Primary Mean state anxiety Assessed using scores from the State-Trait Anxiety Inventory- State scale. Higher scores indicate higher levels of anxiety. This questionnaire is a measure of state and trait anxiety containing 40 items in total (20 for trait; 20 for state). Only the state scale (20 items) will be used in current research to measure situational anxiety. Participants are asked to agree or disagree with anxiety-related statements on a scale of 1-4. 2 weeks postpartum
Primary Mean state anxiety Assessed using scores from the State-Trait Anxiety Inventory- State scale. Higher scores indicate higher levels of anxiety. This questionnaire is a measure of state and trait anxiety containing 40 items in total (20 for trait; 20 for state). Only the state scale (20 items) will be used in current research to measure situational anxiety. Participants are asked to agree or disagree with anxiety-related statements on a scale of 1-4. 4 weeks postpartum
Primary Mean state anxiety Assessed using scores from the State-Trait Anxiety Inventory- State scale. Higher scores indicate higher levels of anxiety. This questionnaire is a measure of state and trait anxiety containing 40 items in total (20 for trait; 20 for state). Only the state scale (20 items) will be used in current research to measure situational anxiety. Participants are asked to agree or disagree with anxiety-related statements on a scale of 1-4. 12 weeks postpartum
Secondary Mean postpartum-specific anxiety symptoms Assessed using scores from the Postpartum-Specific Anxiety Scale. This is a 51-item questionnaire that examines the frequency of maternal and infant focused anxieties experienced by women over the last week. It can be used at any time during the first year following birth and is found to be a valid and reliable measure. Each response is given a score of between 1 and 4 with the maximum score being a total of 204, with higher scores indicating higher levels of anxiety where a score of 112 or above indicating likelihood the individual suffering from an anxiety disorder. Days 0-4 postpartum
Secondary Mean postpartum-specific anxiety symptoms Assessed using scores from the Postpartum-Specific Anxiety Scale. This is a 51-item questionnaire that examines the frequency of maternal and infant focused anxieties experienced by women over the last week. It can be used at any time during the first year following birth and is found to be a valid and reliable measure. Each response is given a score of between 1 and 4 with the maximum score being a total of 204, with higher scores indicating higher levels of anxiety where a score of 112 or above indicating likelihood the individual suffering from an anxiety disorder. 2 weeks postpartum
Secondary Mean postpartum-specific anxiety symptoms Assessed using scores from the Postpartum-Specific Anxiety Scale. This is a 51-item questionnaire that examines the frequency of maternal and infant focused anxieties experienced by women over the last week. It can be used at any time during the first year following birth and is found to be a valid and reliable measure. Each response is given a score of between 1 and 4 with the maximum score being a total of 204, with higher scores indicating higher levels of anxiety where a score of 112 or above indicating likelihood the individual suffering from an anxiety disorder. 4 weeks postpartum
Secondary Mean postpartum-specific anxiety symptoms Assessed using scores from the Postpartum-Specific Anxiety Scale. This is a 51-item questionnaire that examines the frequency of maternal and infant focused anxieties experienced by women over the last week. It can be used at any time during the first year following birth and is found to be a valid and reliable measure. Each response is given a score of between 1 and 4 with the maximum score being a total of 204, with higher scores indicating higher levels of anxiety where a score of 112 or above indicating likelihood the individual suffering from an anxiety disorder. 12 weeks postpartum
Secondary Mean current affect Assessed using scores from the Positive and Negative Affect Scale. This questionnaire has 20 items that describe some feelings and emotions. The participant needs to mark how much they are experiencing these feelings on a scale from 1-5. This produces scores of Positive Affect and Negative Affect; higher scores reflect higher positive or negative mood, respectively. Days 0-4 postpartum
Secondary Mean current affect Assessed using scores from the Positive and Negative Affect Scale. This questionnaire has 20 items that describe some feelings and emotions. The participant needs to mark how much they are experiencing these feelings on a scale from 1-5. This produces scores of Positive Affect and Negative Affect; higher scores reflect higher positive or negative mood, respectively. 2 weeks postpartum
Secondary Mean current affect Assessed using scores from the Positive and Negative Affect Scale. This questionnaire has 20 items that describe some feelings and emotions. The participant needs to mark how much they are experiencing these feelings on a scale from 1-5. This produces scores of Positive Affect and Negative Affect; higher scores reflect higher positive or negative mood, respectively. 4 weeks postpartum
Secondary Mean current affect Assessed using scores from the Positive and Negative Affect Scale. This questionnaire has 20 items that describe some feelings and emotions. The participant needs to mark how much they are experiencing these feelings on a scale from 1-5. This produces scores of Positive Affect and Negative Affect; higher scores reflect higher positive or negative mood, respectively. 12 weeks postpartum
Secondary Mean partner depressive symptoms Using the EPDS-P. This is a 10-item measure adapted from the EPDS. The EPDS-P is a revision of the EPDS to provide a proxy of the partners symptoms of depression, in this study, the mothers will complete the EPDS-P to provide information about paternal depressive symptoms. The scale and scoring of the EPDS-P is the same as the EPDS, though there is no cut-off in the EPDS-P to indicate likelihood for depressive disorder. 0-4 postpartum
Secondary Mean partner depressive symptoms Using the EPDS-P. This is a 10-item measure adapted from the EPDS. The EPDS-P is a revision of the EPDS to provide a proxy of the partners symptoms of depression, in this study, the mothers will complete the EPDS-P to provide information about paternal depressive symptoms. The scale and scoring of the EPDS-P is the same as the EPDS, though there is no cut-off in the EPDS-P to indicate likelihood for depressive disorder. 2 weeks postpartum
Secondary Mean partner depressive symptoms Using the EPDS-P. This is a 10-item measure adapted from the EPDS. The EPDS-P is a revision of the EPDS to provide a proxy of the partners symptoms of depression, in this study, the mothers will complete the EPDS-P to provide information about paternal depressive symptoms. The scale and scoring of the EPDS-P is the same as the EPDS, though there is no cut-off in the EPDS-P to indicate likelihood for depressive disorder. 4 weeks postpartum
Secondary Mean partner depressive symptoms Using the EPDS-P. This is a 10-item measure adapted from the EPDS. The EPDS-P is a revision of the EPDS to provide a proxy of the partners symptoms of depression, in this study, the mothers will complete the EPDS-P to provide information about paternal depressive symptoms. The scale and scoring of the EPDS-P is the same as the EPDS, though there is no cut-off in the EPDS-P to indicate likelihood for depressive disorder. 12 weeks postpartum
Secondary Mean subjective memory scores Prospective and retrospective memory questionnaire. The PRMQ is a 16-item rating scale, designed to assess the frequency of different types of memory failures whereby higher scores indicate greater frequency of memory failures. Participants are asked to score questions of a 5-point scale 1 (never), 2 (rarely), 3 (sometimes), 4 (quite often), 5 (very often). Results can be derived for prospective or retrospective, short-term or long-term, self-cued or environmentally cued. Days 0-4 postpartum
Secondary Mean subjective memory scores Prospective and retrospective memory questionnaire. The PRMQ is a 16-item rating scale, designed to assess the frequency of different types of memory failures whereby higher scores indicate greater frequency of memory failures. Participants are asked to score questions of a 5-point scale 1 (never), 2 (rarely), 3 (sometimes), 4 (quite often), 5 (very often). Results can be derived for prospective or retrospective, short-term or long-term, self-cued or environmentally cued. 2 weeks postpartum
Secondary Mean subjective memory scores Prospective and retrospective memory questionnaire. The PRMQ is a 16-item rating scale, designed to assess the frequency of different types of memory failures whereby higher scores indicate greater frequency of memory failures. Participants are asked to score questions of a 5-point scale 1 (never), 2 (rarely), 3 (sometimes), 4 (quite often), 5 (very often). Results can be derived for prospective or retrospective, short-term or long-term, self-cued or environmentally cued. 4 weeks postpartum
Secondary Mean subjective memory scores Prospective and retrospective memory questionnaire. The PRMQ is a 16-item rating scale, designed to assess the frequency of different types of memory failures whereby higher scores indicate greater frequency of memory failures. Participants are asked to score questions of a 5-point scale 1 (never), 2 (rarely), 3 (sometimes), 4 (quite often), 5 (very often). Results can be derived for prospective or retrospective, short-term or long-term, self-cued or environmentally cued. 12 weeks postpartum
Secondary Mean subjective mood scores Immediate mood scale-This questionnaire contains 22 items developed to assess dynamic components of mood. Participants are asked to rate their current mood state on a continuum using 7-point Likert scales (e.g., happy-sad, distracted-focused, sleepy-alert). For each item, an integer score between 1 and 7 is derived. The total score for this scale is the sum of the scores on all 22 items. Baseline only
Secondary Subjective sleep scores Using the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a validated measure of sleep assessing qualities and patterns within the last month of sleep habits in adults. Seven components of sleep (quality, latency, duration, efficiency, disturbance, use of sleep medication, daytime dysfunction) will be summed to achieve a global PSQI score ranging from 0 to 21 points, where scores above 5 indicates sleep problems. Days 0-4 postpartum
Secondary Subjective sleep scores Using the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a validated measure of sleep assessing qualities and patterns within the last month of sleep habits in adults. Seven components of sleep (quality, latency, duration, efficiency, disturbance, use of sleep medication, daytime dysfunction) will be summed to achieve a global PSQI score ranging from 0 to 21 points, where scores above 5 indicates sleep problems. 2 weeks postpartum
Secondary Subjective sleep scores Using the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a validated measure of sleep assessing qualities and patterns within the last month of sleep habits in adults. Seven components of sleep (quality, latency, duration, efficiency, disturbance, use of sleep medication, daytime dysfunction) will be summed to achieve a global PSQI score ranging from 0 to 21 points, where scores above 5 indicates sleep problems. 4 weeks postpartum
Secondary Subjective sleep scores Using the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a validated measure of sleep assessing qualities and patterns within the last month of sleep habits in adults. Seven components of sleep (quality, latency, duration, efficiency, disturbance, use of sleep medication, daytime dysfunction) will be summed to achieve a global PSQI score ranging from 0 to 21 points, where scores above 5 indicates sleep problems. 12 weeks postpartum
Secondary Blood pressure Resting systolic and diastolic blood pressure will be taken with an ambulatory blood pressure monitor. Measurements will be taken on participants left arm and the mean of three consecutive measurements will be calculated. Days 0-4 postpartum
Secondary Blood pressure Resting systolic and diastolic blood pressure will be taken with an ambulatory blood pressure monitor. Measurements will be taken on participants left arm and the mean of three consecutive measurements will be calculated. 2 weeks postpartum
Secondary Blood pressure Resting systolic and diastolic blood pressure will be taken with an ambulatory blood pressure monitor. Measurements will be taken on participants left arm and the mean of three consecutive measurements will be calculated. 4 weeks postpartum
Secondary Blood pressure Resting systolic and diastolic blood pressure will be taken with an ambulatory blood pressure monitor. Measurements will be taken on participants left arm and the mean of three consecutive measurements will be calculated. 12 weeks postpartum
Secondary Verbal memory Assessed using the Rey Auditory Verbal Learning Test. Days 0-4 postpartum
Secondary Verbal memory Assessed using the Rey Auditory Verbal Learning Test. 2 weeks postpartum
Secondary Verbal memory Assessed using the Rey Auditory Verbal Learning Test. 4 weeks postpartum
Secondary Verbal memory Assessed using the Rey Auditory Verbal Learning Test. 12 weeks postpartum
Secondary Sustained attention and executive functioning Assessed with the Modified Attention Network Task with accuracy and reaction time as outcome measures. Days 0-4 postpartum
Secondary Sustained attention and executive functioning Assessed with the Modified Attention Network Task with accuracy and reaction time as outcome measures. 2 weeks postpartum
Secondary Sustained attention and executive functioning Assessed with the Modified Attention Network Task with accuracy and reaction time as outcome measures. 4 weeks postpartum
Secondary Sustained attention and executive functioning Assessed with the Modified Attention Network Task with accuracy and reaction time as outcome measures. 12 weeks postpartum
Secondary Visuospatial working memory Measured using the Visuospatial n-back with accuracy and reaction time as outcome measures. Days 0-4 postpartum
Secondary Visuospatial working memory Measured using the Visuospatial n-back with accuracy and reaction time as outcome measures. 2 weeks postpartum
Secondary Visuospatial working memory Measured using the Visuospatial n-back with accuracy and reaction time as outcome measures. 4 weeks postpartum
Secondary Visuospatial working memory Measured using the Visuospatial n-back with accuracy and reaction time as outcome measures. 12 weeks postpartum
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1